SynthesisBMC cancer2022
The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.Cancer immunology, immunotherapy : CII · 2024Trial
- Triple-Negative Breast Cancer: Molecular Subtypes; Immune Escape; Limitations of Current Immunotherapy; and the BTLA/HVEM/CD160 Axis as an Emerging Target.Current issues in molecular biology · 2026Review
- Molecular characterization of mammary mucinous cystadenocarcinoma reveals recurrent TP53 and RB1 alterations with frequent PI3K-AKT pathway abnormalities.Virchows Archiv : an international journal of pathology · 2026Article
- Correlation study between inflammatory, nutritional and metabolic indicators and the risk of invasive ductal carcinoma of the breast.Frontiers in oncology · 2026Article
- Breaking Barriers: Immune Checkpoint Inhibitors in Breast Cancer.Pharmaceutics · 2025Review
- Genomic Predictive Biomarkers in Breast Cancer: TheInternational journal of molecular sciences · 2025Review
- Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer.Neoplasia (New York, N.Y.) · 2025Article
- A Novel Disulfidptosis-related lncRNAs Prognostic Signature for Prognosis Predicting and Immune Microenvironment Characterization in Breast Cancer.Current medicinal chemistry · 2025Article
- Molecular Basis of Breast Tumor Heterogeneity.Advances in experimental medicine and biology · 2025Review
- p16 Immunohistochemical Patterns in Triple-Negative Breast Cancer: Clinical and Genomic Similarities of the p16 Diffuse Pattern to pRB Deficiency.Pathobiology : journal of immunopathology, molecular and cellular biology · 2025Article
- Public neoantigens in breast cancer immunotherapy (Review).International journal of molecular medicine · 2024Review
- A novel disulfidptosis-related gene signature predicts overall survival of glioblastoma patients.Future science OA · 2024Article
- Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities.Cancers · 2023Review
- Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.Breast cancer (Tokyo, Japan) · 2023Article
- Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.Frontiers in oncology · 2023Article
- Liquid biopsy biomarkers to guide immunotherapy in breast cancer.Frontiers in immunology · 2023Review
- Activated Mast Cells Combined with NRF2 Predict Prognosis for Esophageal Cancer.Journal of oncology · 2023Article
- Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genes.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a potential genetic biomarker, tumor mutation burden (TMB) has made progress in numerous tumors. There are limited data regarding TMB and its prognostic role is controversial in breast cancer. This systematic review and meta-analysis were conducted to assess the prognostic value of TMB on survival of breast cancer.
methodsThe databases PubMed, Embase, Web of Science, and Cochrane Library were searched for articles published through May 31, 2022. Moreover, effective data were extracted from included studies and calculated pooled effects of hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) by STATA 16.0. Heterogeneity was conducted by the I
resultsThey were up to 1,722 patients collected from sixteen cohorts for this analysis. The pooled effects of HR for both OS (HR: 1.14, 95% CI: 0.83,1.58, p > 0.01) and PFS (HR: 0.96, 95% CI: 0.53,1.71, p > 0.01) indicated no statistically significant difference in the high TMB and low TMB group. In immune checkpoint inhibitors (ICIs) subgroup, high TMB patients demonstrated benefit of OS (HR: 0.72, 95% CI: 0.59,0.87, p = 0.001) and PFS (HR: 0.52, 95% CI: 0.35,0.77, p < 0.001), whereas difference was not statistically significant in the non-ICIs subgroup (OS, HR:1.76, 95% CI: 0.97,3.20, p = 0.062; PFS, HR:2.31, 95% CI: 0.89,5.97, p = 0.086). In addition, sensitivity analysis revealed that the pooled effects were stable. The funnel plot and Begg's test suggested the absence of publication bias.
conclusionMeta-analysis revealed that the prognostic relevance of TMB in breast cancer is limited in scope. High TMB may be associated with longer survival only in ICIs-based treatment, but the association is not evident in non-ICIs-based treatment.
trial registration[ https://www.crd.york.ac.uk/PROSPERO ], Prospective Register of Systematic Reviews (PROSPERO), identifier: CRD42022342488.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.